<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255331</url>
  </required_header>
  <id_info>
    <org_study_id>2015-442 R01 AR064840</org_study_id>
    <nct_id>NCT02255331</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging as a Biomarker For Adverse Local Tissue Reaction In Individuals With Hip Arthroplasty</brief_title>
  <official_title>Magnetic Resonance Imaging as a Biomarker For Adverse Local Tissue Reaction In Individuals With Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a total hip replacement may require early revision surgery due to an adverse
      local tissue reaction or bone resorption that occurs due to wear debris released from the
      implant. A non-invasive imaging biomarker does not exist to identify or to follow total hip
      replacement patients who are most at risk for suffering this type of premature implant
      failure. This study will evaluate magnetic resonance imaging (MRI) as a biomarker to predict
      a failing hip replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total hip arthroplasty (THA) with metal-on-polyethylene (MOP) bearing materials have
      excellent survival rates but a common cause for implant failure is aseptic loosening caused
      by biologic reaction to wear debris. Alternative bearing surfaces, such as ceramics and
      metals, were developed as an alternative to MOP to reduce osteolysis due to polyethylene
      wear.

      The use of metal-on-metal (MOM) hip resurfacing arthroplasty (HRA) implants was initially
      advocated due to the perceived advantages over MOP; however, reactions to MOM wear debris in
      the expanded capsule have become a common cause of premature implant failure due to adverse
      local tissue reactions. Furthermore, monitoring local response to an implants requires high
      soft tissue contrast, as the adverse reactions are generated by the host synovial response.
      Magnetic resonance imaging (MRI) has superior soft tissue contrast but has traditionally been
      limited by the artifact generated by the components.

      In this study, the investigators propose to develop MRI as a biomarker to detect adverse
      local tissue reactions for all bearing combinations and modular connections in THA.
      Individuals indicated for revision THA surgery will be recruited for pre-operative MRI
      studies, intra-operative tissue sampling for histologic analysis, and post-operative wear
      analysis of the retrieved implant. Correlations between the MRI datasets and the histologic
      and wear assessments will be performed and will be used to develop a predictive diagnostic
      tool for the management of THA patients. This predictive tool will be applied to cohort of
      individuals with primary THA to longitudinally monitor disease progression in patients with
      different individual risk factors and implant bearing surfaces.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establishment of a composite MRI predictive tool to detect adverse local tissue reactions, bone loss and wear debris in patients.</measure>
    <time_frame>An expected average of 1 year post-operatively</time_frame>
    <description>This predictive tool is a composite outcome measure, utilizing the input of:
Evaluation of MR images: Presence, location, type and volume of synovitis, Synovial thickness, Impression of synovium, Presence and location of decompression of synovitis, Presence and location of low signal intensity deposits, Presence of soft tissue edema, Presence and location of dehiscence, Presence, location and volume of osteolysis, Assessment of implant loosening, Presence of and location of neurovascular compression, Disruption of abductors due to distended pseudocapsule, Presence of enlarged lymph nodes and presence and grading of adverse local tissue reaction.
Pre-operative blood metal ion levels
Pre-operative Hip disability and Osteoarthritis Outcome Score
Pathologic evaluation of tissue obtained intra-operatively
Intra-operative grade of soft tissues around the primary total hip replacement
Implant wear analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinally monitor disease progression in patients with different individual risk factors and implant bearing surfaces and characteristics</measure>
    <time_frame>This outcome will be measured at 4 different time points: Initial office visit, 1 year follow-up, 2 year follow-up, 3 year follow-up.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mode of total hip arthroplasty failure</measure>
    <time_frame>An expected average of 1 year post-operatively</time_frame>
    <description>Patients will be classified as symptomatic with mechanical symptoms and symptomatic with unexplained pain. These groups are based on the categories used by the National Joint Registry of England and Wales. Patients presenting with loosening, instability, or malalignment will be classified as &quot;mechanical&quot; failure. In cases of loosening, patients will be categorized as having acetabular or femoral loosening, only when documented intra-operatively by the surgeon. Patients presenting with pain not attributable to implant loosening, instability, or component malposition will be classified as &quot;unexplained&quot; failure. No specific unit of measure will be used for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood serum metal ion levels</measure>
    <time_frame>Measurement at an expected average of 1 year post operatively for revision total hip arthroplasty patients, or at initial office visit, 1 year follow-up, 2 year follow-up, and 3 year follow-up for individuals being monitored longitudinally.</time_frame>
    <description>Blood samples will be drawn into lithium-heparin containing tubes with non-contamination precautions, and analyzed with high resolution inductively coupled mass spectrometry for the most accurate assessment of Cobalt and Chromium metal ion levels, to be measured in parts per million (ppm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic evaluation of implant orientation - anteversion and inclination</measure>
    <time_frame>Measurement at an expected average of 1 year post operatively for revision total hip arthroplasty patients, or at initial office visit for individuals being monitored longitudinally.</time_frame>
    <description>The assessment of hip replacement acetabular component position will be performed using the Einzel-Bild-Roentgen-Analysis (EBRA) software. The femoral stem-shaft angle will be measured in the frontal plane. The acetabular inclination angle will be measured in the frontal plane. The acetabular anteversion angle will be measured in the lateral plane. All measurements will be expressed in units of degrees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI evaluation of soft tissues surrounding total hip arthroplasty</measure>
    <time_frame>Measurement at an expected average of 1 year post operatively for revision total hip arthroplasty patients, or at initial office visit, 1 year follow-up, 2 year follow-up, and 3 year follow-up for individuals being monitored longitudinally.</time_frame>
    <description>Evaluation of MR images: Presence, location, type and volume (measurement units of mm^3) of synovitis, Synovial thickness (measurement units of mm), Impression of synovium, Decompression of synovitis, Decompression into Trochanteric Bursa, Decompression into Iliopsoas, Presence and location of low signal intensity deposits, Presence of soft tissue edema, Presence and location of dehiscence, Presence, location and volume (measurement units of mm^3) of osteolysis, Assessment of implant loosening, Presence of and location of neurovascular compression, Disruption of abductors due to distended pseudocapsule, Presence of enlarged lymph nodes and presence and grading of adverse local tissue reaction. All quantitative values have the units of measurement indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI multi-acquisition variable resonance image combination (MAVRIC) phase contrast</measure>
    <time_frame>Measurement at an expected average of 1 year post operatively for revision total hip arthroplasty patients, or at initial office visit, 1 year follow-up, 2 year follow-up, and 3 year follow-up for individuals being monitored longitudinally.</time_frame>
    <description>The raw data from MR images will be processed to aid in defining the extent of an adverse local tissue reaction. This outcome measure will be measured in the units of Hertz (Hz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative damage assessment</measure>
    <time_frame>Measurement during revision surgery for total hip arthroplasty patients</time_frame>
    <description>A subjective scoring system will be used for intraoperative damage assessment of the hip joint. The system is based on a 0 to 3 scale denoting the level of involvement of the soft tissues surrounding the joint (capsule, synovium, and muscle): 0 = Normal tissue; 1 = Fluid collection Â± mild synovial reaction with or capsular dehiscence; 2 = the same findings as a score of 1, but with moderate synovial reaction; and 3 = the same findings as a score of 2, but with the addition of damage to the abductor muscle and/or osteolysis. No specific unit of measure will be used for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic analysis of retrieved tissues</measure>
    <time_frame>Measurement at an expected average of 1 year post operatively for revision total hip arthroplasty patients.</time_frame>
    <description>Histological evaluation will be using a 10 point aseptic lymphocytic vasculitis associated lesion (ALVAL) score to assess tissue reaction to a total hip replacement. The ALVAL score is a summation of individual grades assigned to the integrity of the synovial lining, presence and extent of inflammatory cell infiltrates, necrosis and tissue organization.
We will use a supplemental grading system intended for metal-on-poly and ceramic implants since ALVAL grading is used primarily for metal-on-metal (MOM) articulations and may not detect similar features of wear debris in non-MOM articulations, polyethylene, metal or corrosion products. The presence of ceramic and polyethylene particles and the relative number of macrophages, giant cells, histiocytes, acute or chronic inflammatory cells, and presence of necrotic tissue will be graded using the scale of: 1) absent (-), little (+), moderate (++), extensive (+++). No specific unit of measure will be used for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant retrieval wear analysis</measure>
    <time_frame>Measurement at an expected average of 1 year post operatively for revision total hip arthroplasty patients.</time_frame>
    <description>The bearing surfaces of the femoral heads and acetabular components, the neck trunnion of the total hip replacement femoral stems, and the matching female tapers of the total hip replacement heads retrieved at surgery will be scanned with a technique that utilizes a non-contact measurement method to calculate volumetric wear (measurement units of mm^3) and linear wear (measurement units of mm).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Complications; Arthroplasty</condition>
  <condition>Complications; Arthroplasty, Mechanical</condition>
  <arm_group>
    <arm_group_label>Retrieval Analysis</arm_group_label>
    <description>You qualify for this arm of the study if you:
Have a metal-on-metal total hip replacement , or
Have a modular design metal-on-polyethylene total hip replacement, or
Have a hip resurfacing implant, or
Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation, or
Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or
Have a metal-on-polyethylene total hip replacement greater than 1 year old, or
Have an infected total hip replacement
You do not qualify for this arm of the study if you:
1. Have occupational exposure to cobalt or chromium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal Evaluation</arm_group_label>
    <description>You qualify for this arm of the study if you:
Have a hip resurfacing implant, or
Have a modular design metal-on-polyethylene total hip replacement, or
Have a traditional metal-on-poly total hip replacement, or
Have a total hip replacement with a ceramic component.
Are asymptomatic at 1 years post-operative
You do not qualify for this arm of the study if you:
1. Have occupational exposure to cobalt or chromium</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. A small sample of soft tissues surrounding a total hip replacement will be retained for
      histological evaluation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals who will be having revision surgery of a total hip replacement, or individuals
        who currently have their first (primary) total hip replacement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort #1:

          1. Have a metal-on-metal total hip replacement , or

          2. Have a modular design metal-on-polyethylene total hip replacement, or

          3. Have a hip resurfacing implant, or

          4. Have a total hip replacement with a ceramic component undergoing revision for any
             reason, including recurrent dislocation, or

          5. Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or

          6. Have a metal-on-polyethylene total hip replacement greater than 1 year old, or

          7. Have an infected total hip replacement

        Cohort #2:

          1. Have a hip resurfacing implant, or

          2. Have a modular design metal-on-polyethylene total hip replacement, or

          3. Have a traditional metal-on-poly total hip replacement, or

          4. Have a total hip replacement with a ceramic component.

          5. Are asymptomatic at 1 years post-operative

        Exclusion Criteria:

        Cohorts 1&amp;2:

        1. Have occupational exposure to cobalt or chromium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew F Koff, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hollis G Potter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew F Koff, PhD</last_name>
    <phone>212-774-2103</phone>
    <email>koffm@hss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Parina Shah, MS</last_name>
    <phone>212-774-2496</phone>
    <email>shahp@hss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-774-2103</phone>
      <email>koffm@hss.edu</email>
    </contact>
    <contact_backup>
      <last_name>Parina Shah, MS</last_name>
      <phone>212-774-2496</phone>
      <email>shahp@hss.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew F Koff, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hollis G Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hss.edu/research-magnetic-resonance-imaging-lab.asp</url>
    <description>Hospital for Special Surgery MRI Laboratory</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthroplasty</keyword>
  <keyword>Replacement</keyword>
  <keyword>Hip</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will encourage the sharing of our final research data to enable further exploration of the data not presented in the application and for encouraging other individuals to develop new methods of data analysis. The data will be organized by subject number and by date of procedure (e.g. radiographs, MRI, serum metal ion levels, histology, wear analysis, etc.) for ease of identifying a specific dataset. The data will be stored on our servers and back-up drives. Individuals requesting electronic data will be given a link to a private web server to download the requested information, or will be requested to pay a nominal fee to burn the data to CD or DVD or to download to an individual's blank external hard drive, and for mailing charges depending on the type of data requested. Our goal is to make the data as easily accessible to the public as possible.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

